Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403626 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL2087641 | 0.92 | NPC1 (0.71) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL4279981 | 0.91 | HSD17B10 (0.61) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL9356016 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHPGDKMT2A | |
| SCHEMBL11286951 | 0.88 | NPC1 (0.78) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL2063068 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL5750152 | 0.88 | NPC1 (0.56) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL1810999 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL9597843 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL13434462 | 0.87 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-7745431-B2 | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA ACQUISITION CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1581206-A4 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2004050616-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6638928-B1 | Benzodiazepines administered for irritable bowel syndrome and nonulcer dyspepsia. | VELA PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-0931119-B1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO LTD (KR) | 2001-12-05 | — | — | EP | disclosed |
| EP-0931119-A1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1999-07-28 | — | — | EP | disclosed |
| US-5755997-A | Chiral compounds with liquid crystalline nature | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1998-05-26 | — | — | US | disclosed |
| WO-1998014529-A1 | CHIRAL COMPOUNDS WITH LIQUID CRYSTALLINE NATURE AND FERROELECTRIC LIQUID CRYSTAL DEVICE ADOPTING THE SAME | SAMSUNG DISPLAY DEVICES CO., LTD. (KR) | 1998-04-09 | — | — | WO | disclosed |
| US-5196422-A | Antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5089513-A | Antiinflammatory agents; antiallergens; asthma; side effect reduction | ICI PHARMA (FR) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | SMN1; SMN2 3787/4885NPC1 1480/4885RAB9A 2968/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | SMN1; SMN2 2282/4885NPC1 844/4885RAB9A 1836/4885 |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | SMN1; SMN2 3441/4885NPC1 874/4885RAB9A 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.